Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-α Biosimilar with Imraldi® (adalimumab)
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi® , a biosimilar referencing Humira® 1 (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis and uveitis.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824006317/en/
With the EC’s marketing authorization of Imraldi® , Samsung Bioepis becomes the industry’s first to receive European approvals for biosimilars referencing all three anti-TNF-α blockbusters. Benepali® (etanercept) and Flixabi® (infliximab) received EC marketing authorization in January 2016 and May 2016, respectively.
“We are proud to become the industry’s first to obtain European approval for a third TNF inhibitor. This is a testament to our agile biologics development platform, which has allowed us to develop approved biosimilars in less time at lower cost,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more patients and healthcare systems across Europe will benefit from biosimilars.”
The EC approval of Imraldi® applies to all 28 European Union (EU) member states as well as the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Biogen will commercialize Imraldi® in the EU and EEA member states.
The EC approval of Imraldi® follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2017.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
1 Humira ® is a registered trademark of AbbVie Inc.
Samsung Bioepis Co., Ltd.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-CITI-PRIVATE-BANK18.6.2018 16:03 | pressemeddelelse
Citi Private Bank Congratulates Fernando Alonso on the 24 Hours of Le Mans Win
MI-INTEVA-PRODUCTS18.6.2018 15:33 | pressemeddelelse
Inteva Products Receives Top Innovation Award for Revolutionary Stitching Process
PROCTER-&-GAMBLE18.6.2018 14:27 | pressemeddelelse
P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity
NY-NORSK-TITANIUM18.6.2018 14:02 | pressemeddelelse
Norsk Titanium Marks Milestone in U.S. Production
MA-AVEDRO18.6.2018 14:02 | pressemeddelelse
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus
VERTEX-PHARMACEUTICALS18.6.2018 13:02 | pressemeddelelse
Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum